Supplementary Online Content

Dorabawila, V, et al. Effectiveness of the BNT162b2 vaccine among children 5-11 and 12-17 years in New York after the Emergence of the Omicron Variant

eMethods

eTable 1. New Cases among Children Newly Vaccinated from December 13, 2021 to January 2, 2022

eTable 2. Days Since Series Completion by Age as of January 3, 2022 and January 31, 2022

eTable 3. New Hospitalizations with Primary Reason for Admissions being for COVID-19, Incidence Rate Ratio, and Vaccine Effectiveness, Children Ages 5-17

eTable 4. Time since vaccination analysis: Rates per 100,000, Incidence Rate Ratio, and Vaccine Effectiveness

eMethods

Dataset construction

Vaccination registry (NYSIIS/CIR) COVID-19 data were combined and deduplicated based on first name, last name, date of birth (DOB), and ZIP code then matched to laboratory data (ECLRS) using a deterministic algorithm based on first name, last name, and DOB, and to hospital admissions (HERDS) based on initials, sex, DOB, and ZIP code. Partially and fully vaccinated children in each age group were subtracted from the census population in the applicable age groups to arrive at the unvaccinated children count. Partially vaccinated children were excluded from the analyses.

Time since vaccination analysis

This analysis included three weekly cohorts of children who completed the primary series from December 13, 2021 to January 2, 2022. There were 1,539,762 person days of children a ged 5-11 years and 151,005 person days of children aged 12-17 years (eTable 1). The number of children aged 5-11 years included in this analysis was higher compared those 12-17 years, largely as a function of when the vaccine was authorized for these age groups. US Food and Drug Administration emergency use authorization for children 16-17 years was given on December 11,2020, 12-15 years on May 10, 2021 and aged 5-11 years on October 29, 2021.

Outcomes among the three weekly cohorts were a ranged into time-since-vaccination categories during the four January 3-30, 2022 follow-up weeks by combining cohorts as illustrated via colored diagonal cells in eTable 1. For example, cases within \leq 13 days of full-vaccination (grey shading) are children that were vaccinated between December 27-January 2 with an outcome window between January 3-9, 2022. Similarly, cases 28-34 days after full-vaccination (light-blue shading) represented the sum of the following 3 groups: (1) persons vaccinated between December 12-19 and with cases between January 10-16 (1,234 cases in the 5-11 age group, for example); (2) persons vaccinated between December 20-26 and with cases between January 17-23 (635 cases in the 5-11 age group); and (3) persons vaccinated between December 27-January 2 and with cases between January 24-30 (204 cases in the 5-11 age group).

Incident case rates a mong the vaccinated, by time-since-vaccination interval, were constructed. The numerator, cases, was the sum in each time-since-vaccination group (2,073 in the example of cases between 28-34 days in the 5-11 age group). In this example, there were 3 vaccination groups (light blue) that were combined, per the colored diagonals in eTable 1. The denominator is the number of children observed fully-vaccinated during the time-since-vaccination interval and contributing to the numerator. In the example of 28-34 days, all three weekly cohorts were vaccinated for that interval, thus 1,539,762 person days of children 5-11 years contributed to the denominator. Thus incidence rates for those vaccinated (R_V) were $R_V = \frac{\sum_{i=1}^{k} C_{V,i}}{\sum_{i=1}^{k} N_{V,i}}$, with $var(R_V) = \frac{\sum_{i=1}^{k} C_{V,i}}{(\sum_{i=1}^{k} N_{V,i})^2}$, where *i* is the cohort, *k* is the number of cohorts combined, $C_{V,i}$ is the number of cases among vaccinated cohort members, and $N_{V,i}$ is the number of vaccinated person days observed in the cohort for the interval.¹

Rates among an unvaccinated comparison group were constructed from unvaccinated rates in the same weeks contributing to a given time-since-vaccination interval, directly standardized to the person-time of those vaccinated, as follows. The directly-standardized rate for the unvaccinated (DSR_U) , was estimated as $DSR_U =$

 $\frac{\sum_{i=1}^{k} N_{V,i} R_{U,i}}{\sum_{i=1}^{k} N_{V,i}}, \text{ with } var(DSR_U) = \frac{\sum_{i=1}^{k} \frac{(N_{V,i})^2 R_{U,i}}{N_{U,i}}}{(\sum_{i=1}^{k} N_{V,i})^2}, \text{ where } R_{U,i} \text{ is the unvaccinated case rate } (\frac{C_{U,i}}{N_{U,i}}, \text{ cases among})$ unvaccinated / unvaccinated persons, as calculated for the open-cohort method) and $N_{U,i}$ is number of unvaccinated persons in a given week contributing to the interval (eTable 4).^{2,3}

The incidence rate ratio (IRR) for each time-since-vaccination interval was estimated as $IRR = \frac{DSR_U}{R_V}$, with $var(ln[IRR]) = \frac{var(R_V)}{R_V^2} + \frac{var(DSR_U)}{DSR_U^2}$, and 95% $CI = e^{\ln (IRR) \pm 1.96\sqrt{var(\ln(IRR))}}$.

	Person Days	Follow Up Week						
Cohort	Newly Vaccinated	Jan 3 – 9	Jan 10-16	Jan 17-23	Jan 24-30			
5-11 Years					_			
Dec 13-19	476,265	1,808	1,234	781	472			
Dec 20-26	642,013	1,536	1,054	635	403			
Dec 27-Jan 2	421,484	712	522	320	204			
Age 12-17 Yea	rs							
Dec 13-19	46,414	132	82	42	22			
Dec 20-26	54,054	126	65	33	23			
Dec 27-Jan 2	50,537	84	55	41	15			

eTable 1: New Cases among Children Newly Vaccinated from December 13, 2021 to January 2, 2022^a

^a Days since full vaccination are indicated in background color: Grey: <=13 days, Orange: 14-20 days, Yellow: 21-27 days, Lightblue: 28-34 days, Green: 35-41 days, Dark-blue: 42-48 days

Age at Days from Series Completion to 1/3/22					Days from Series Completion to 1/31/22				
Series Completion	# Children	Mean	Median	SD	# Children	Mean	Median	SD	
5-11 Total	247,953	28	28	13	384,284	46	51	18	
5	27,034	28	28	10	43,274	45	50	16	
6	30,922	28	28	12	48,338	46	51	17	
7	33,642	28	28	9	51,971	46	51	16	
8	35,120	28	28	21	54,134	46	51	22	
9	38,113	28	28	10	58,776	46	51	16	
10	40,752	28	28	10	62,236	46	51	16	
11	42,370	28	28	14	65,555	46	51	19	
12-17 Total	884,233	168	187	60	914,257	191	211	67	
12	146,944	143	145	58	57,061	162	165	66	
13	132,238	160	177	51	136,536	183	201	57	
14	39,649	162	180	54	43,504	185	205	60	
15	141,304	163	185	51	45,092	187	209	57	
16	159,003	185	204	66	162,944	208	231	71	
17	165,095	191	211	64	169,120	214	237	70	

eTable 2: Days Since Series Completion by Age as of January 3, 2022 and January 31, 2022

	New Hospitalizations				Incidence Rate Ratios, Vaccine Effectiveness			
Week	Vaccinated		Unvaccinated					
	n	% of COVID-19	n	% of COVID-	IRR ^a	(95% CI)	VE ^a	(95% CI)
		admissions		19 admissions				
5-11 years								
Dec. 13-19	0	0%	6	33%	+inf.	(0.1, +inf.)		(-1256, 100%)
Dec. 20-26	2	100%	29	58%	2.1	(0.5, 18.2)	53%	(-87, 95%)
Dec. 27-Jan. 2	1	33%	43	54%	8.8	(1.5, 356.0)	89%	(33, 100%)
Jan. 3-9	3	60%	31	40%	2.5	(0.8, 12.8)		(-28, 92%)
Jan. 10-16	1	17%	29	43%	8.1	(1.3, 330.5)		(25, 100%)
Jan. 17-23	4	50%	13	28%	1.0	(0.3, 4.4)		(-209, 77%)
Jan. 24-30	2	25%	15	36%	2.7	(0.6, 24.8)		(-56, 96%)
December 13 – January 30	13	41%	166	43%	2.9	(1.6, 5.5)	65%	(39, 82%
12 – 17 years								
Nov. 29-Dec. 5	0	0%	8	40%	+inf.	(2.9, +inf.)		(65, 100%)
Dec. 6-12	0	0%	6	55%	+inf.	(2.0, +inf)	100%	(51, 100%)
Dec. 13-19	3	50%	8	35%	4.8	(1.1, 27.9)		(13, 96%)
Dec. 20-26	5	28%	19	42%	7.0	(2.5, 23.9)	86%	(60, 96%)
Dec. 27-Jan. 2	15	39%	28	36%	3.5	(1.8, 7.1)	72%	(45, 86%)
Jan. 3-9	10	21%	24	26%	4.6	(2.1, 10.8)	78%	(53, 91%)
Jan. 10-16	9	22%	23	27%	5.0	(2.2, 12.4)		(55, 92%)
Jan. 17-23	5	15%	12	18%	4.8	(1.6, 17.5)		(37, 94%)
Jan. 24-30	1	5%	8	20%	16.4	(2.0, 131.0)	94%	(51, 99%)
December 13 – January 30	48	23%	122	28%	4.9	(3.5, 7.0)	80%	(71, 86%)

eTable 3: New Hospitalizations with Primary Reason for Admissions being for COVID-19, Incidence Rate Ratio, and Vaccine Effectiveness, Children Ages 5-17

^a IRR and VE calculated on rates limited to only those COVID-19 admissions with primary reason indicated as "for COVID-19". This represents a conservative estimate, since admissions with other primary reasons may have had SARS-CoV-2 infection as a contributing, exacerbating factor. Additionally, this may not be discernable at the time of admissions, without further clinical workup and record review.

5-11	Jan 3 – 9	Jan 10-16	Jan 17-23	Jan 24-30
Rates per 100,000				
Dec 13-19	379.6	259.1	164.0	99.1
Dec 20-26	239.2	164.2	98.9	62.8
Dec 27-Jan 2	168.9	123.8	75.9	48.4
Unvaccinated	484.0	256.3	130.7	70.0
Dec 13-19	284.4	176.7	90.5	47.4
Dec 20-26	233.1	120.3	61.1	42.6
Dec 20-20 Dec 27-Jan 2	166.2	120.3	81.1	29.7
Unvaccinated	706.5	344.8	169.1	88.4
Incidence Rate Ratio	700.0			
5-11				
Dec 13-19	1.27	0.99	0.80	0.71
Dec 20-26	2.02	1.56	1.32	1.12
Dec 27-Jan 2	2.86	2.07	1.72	1.45
12-17				
Dec 13-19	2.48	1.95	1.87	1.86
Dec 20-26	3.03	2.87	2.77	2.08
Dec 27-Jan 2	4.25	3.17	2.08	2.98
Vaccine				
Effectiveness				
5-11				
Dec 13-19	21.6%	-1.1%	-25.5%	-41.5%
Dec 20-26	50.6%	35.9%	24.3%	10.3%
Dec 27-Jan 2	65.1%	51.7%	41.9%	30.9%
12-17				
Dec 13-19	59.7%	48.8%	46.5%	46.4%
Dec 20-26	67.0%	65.1%	63.9%	51.8%
Dec 27-Jan 2	76.5%	68.4%	52.0%	66.4%

eTable 4: Time since vaccination analysis: Rates per 100,000, Incidence Rate Ratio, and Vaccine Effectiveness

eReferences

1. Lash TL, VanderWeele TJ, Haneuse S, Rothman KJ. *Modern Epidemiology* (3th ed.). Philadelphia, PA: Wolters Kluwer; 2021

2. Direct Standardization. <u>https://www.statsdirect.com/help/rates/standardize_compare_two_rates.htm</u>. Accessed on February 9, 2022.

3. Chiang CL. Standard error of the age-adjusted death rate. US Department of Health, Education and Welfare: Vital Statistics Special Reports 1961;47:271-285.